Lanean...

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains

The characterization of kinases as oncogenic drivers has led to more than 30 FDA-approved targeted kinase inhibitors for cancer treatment. Unfortunately, these therapeutics fail to have clinical durability because of adaptive responses from the kinome and transcriptome that bypass inhibition of the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cell Oncol
Egile Nagusiak: Stuhlmiller, Timothy J., Miller, Samantha M., Johnson, Gary L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2015
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4845204/
https://ncbi.nlm.nih.gov/pubmed/27308566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1052182
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!